Shares declined 1.4% after Outset Medical reported a modest revenue decline and continued lumpiness in capital sales, which dampened top-line growth and raised caution on near-term momentum despite margin expansion and a stable outlook.

• Revenue totaled $27.9 million, down 6% year-over-year, driven by variability in capital order timing affecting product sales.
• Product margin expanded to over 52%, reaching record levels due to margin improvement programs and favorable mix.
• Treatments and service segments performed in line with expectations, contributing to stable gross margins.
• The company reaffirmed full-year guidance, supported by a robust late-stage pipeline and upcoming launch of next-generation Tablo with enhanced cybersecurity features.
• Management emphasized disciplined cash usage and operational efficiencies but acknowledged lumpiness in capital equipment orders persists, limiting near-term revenue visibility.